» Articles » PMID: 18417668

Interlaboratory Comparison of Results of an Anthrax Lethal Toxin Neutralization Assay for Assessment of Functional Antibodies in Multiple Species

Overview
Date 2008 Apr 18
PMID 18417668
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The anthrax lethal toxin neutralization assay (TNA) will likely be used to correlate the protection offered by new anthrax vaccines in animal models to the immunogenicity that will be provided in humans. TNA data are being generated in several different laboratories to measure the immune responses in rabbits, nonhuman primates, and humans. In order to compare data among species and laboratories, a collaborative study was conducted in which 108 samples from the three species were analyzed in seven independent laboratories. Six of the seven laboratories had participated in an interlaboratory technology transfer of the TNA. Analysis of the titration curves generated by samples from each species indicated that the behaviors of the samples from all species were similar; the upper and lower asymptotes and the slopes of the curves were less than 30% divergent from those for human reference material. Dilutional linearity was consistent among samples from each species, with spike to effective dilution at 50% inhibition (ED(50)) slopes of less than 1.2 for all species. Agreement among the laboratories with consensus values was within 10% of the ED(50)s for all samples and within 7.5% of the quotients of the test sample ED(50) and the reference standard ED(50) (NF(50)s) for all samples. The relative standard deviations obtained when data from all laboratories and for all species were combined were 45% for the ED(50)s and 35% for the NF(50)s. These precision data suggest that the NF(50) readout may normalize the values generated by different laboratories. This study demonstrates that the TNA is a panspecies assay that can be performed in several different laboratories with a high degree of quantitative agreement and precision.

Citing Articles

Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis.

Piliper E, Reed J, Greninger A Microbiol Spectr. 2024; :e0211524.

PMID: 39470275 PMC: 11619414. DOI: 10.1128/spectrum.02115-24.


Visualization of immune pathways that enhance the neutralizing antibody response to vaccines after primary immunization.

Verma A, De Pascalis R, Mocca C, Li X, Burns D mBio. 2024; 15(3):e0003724.

PMID: 38334423 PMC: 10936199. DOI: 10.1128/mbio.00037-24.


Immunological Evidence of Variation in Exposure and Immune Response to in Herbivores of Kruger and Etosha National Parks.

Ochai S, Crafford J, Hassim A, Byaruhanga C, Huang Y, Hartmann A Front Immunol. 2022; 13:814031.

PMID: 35237267 PMC: 8882864. DOI: 10.3389/fimmu.2022.814031.


Interlaboratory comparison for the Filovirus Animal Nonclinical Group (FANG) anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay.

Anderson M, Niemuth N, Sabourin C, Badorrek C, Bounds C, Rudge Jr T PLoS One. 2020; 15(8):e0238196.

PMID: 32841291 PMC: 7447032. DOI: 10.1371/journal.pone.0238196.


Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen.

Verma A, Ngundi M, Price G, Takeda K, Yu J, Burns D mBio. 2018; 9(1).

PMID: 29487236 PMC: 5829829. DOI: 10.1128/mBio.00209-18.


References
1.
Campbell J, Clement K, Wasserman S, Donegan S, Chrisley L, Kotloff K . Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin. 2007; 3(5):205-11. DOI: 10.4161/hv.3.5.4459. View

2.
Lacy D, Collier R . Structure and function of anthrax toxin. Curr Top Microbiol Immunol. 2002; 271:61-85. DOI: 10.1007/978-3-662-05767-4_4. View

3.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

4.
Ivins B, Pitt M, Fellows P, Farchaus J, Benner G, Waag D . Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 1998; 16(11-12):1141-8. DOI: 10.1016/s0264-410x(98)80112-6. View

5.
SEMENOVA V, Steward-Clark E, Stamey K, Taylor Jr T, Schmidt D, Martin S . Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol. 2004; 11(5):919-23. PMC: 515271. DOI: 10.1128/CDLI.11.5.919-923.2004. View